1
|
Kanamori K, Kurita D, Hirano Y, Ishiyama K, Oguma J, Masutomi K, Daiko H. Does synchronous early head and neck cancer with esophageal cancer need treatment after preoperative chemotherapy? Gen Thorac Cardiovasc Surg 2021; 70:280-284. [PMID: 34837129 DOI: 10.1007/s11748-021-01744-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Accepted: 11/11/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Treatment options for patients with resectable thoracic esophageal squamous cell cancer (ESCC) and synchronous head and neck cancer (HNC) are unclear. Little has been reported about the effects of chemotherapy on early HNC. The aim of this study was to investigate the treatment outcomes of resectable thoracic ESCC with synchronous early HNC. METHODS We retrospectively reviewed 37 patients undergoing esophagectomy for thoracic ESCC with synchronous early HNC from January 2008 to December 2018. RESULTS Among 37 patients who had synchronous early HNC, 27 patients received preoperative therapy for ESCC before HNC treatment, and 16 of 27 patients achieved a complete response for HNC by preoperative chemotherapy. Fifteen of 16 patients did not receive additional treatment, and regional recurrence of HNC was not observed. In one other case, an oral excision was performed, but no cancer cell remnants were found pathologically. No significant difference in overall survival and disease-free survival was observed between 15 patients with follow-up and 22 patients with surgery or radiation. CONCLUSION Our results indicate that early HNC with comorbid ESCC could be followed up without additional treatment if preoperative chemotherapy is successful.
Collapse
Affiliation(s)
- Kohei Kanamori
- Department of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.,Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Japan
| | - Daisuke Kurita
- Department of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Yuki Hirano
- Department of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Koshiro Ishiyama
- Department of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Junya Oguma
- Department of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Kenkichi Masutomi
- Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Japan.,Division of Cancer Stem Cell, National Cancer Research Institute, 5-5-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Hiroyuki Daiko
- Department of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
| |
Collapse
|
2
|
Laccourreye O, Marret G, Rubin F, Fabre E, Badoual C, Oudard S, Bonfils P, Lisan Q. Ten‐year outcome of curative “exclusive” chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response. Head Neck 2019; 41:2190-2196. [DOI: 10.1002/hed.25674] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 01/08/2019] [Accepted: 01/10/2019] [Indexed: 11/08/2022] Open
Affiliation(s)
- Ollivier Laccourreye
- Department of Otorhinolaryngology ‐ Head and Neck SurgeryUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Grégoire Marret
- Department of Medical OncologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | | | - Elizabeth Fabre
- Department of Medical OncologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Cécile Badoual
- Department of PathologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Stéphane Oudard
- Department of Medical OncologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Pierre Bonfils
- Department of Otorhinolaryngology ‐ Head and Neck SurgeryUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Quentin Lisan
- Department of Otorhinolaryngology ‐ Head and Neck SurgeryUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| |
Collapse
|
3
|
Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma? Pathol Oncol Res 2017; 24:931-935. [PMID: 29130149 DOI: 10.1007/s12253-017-0336-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Accepted: 10/20/2017] [Indexed: 12/13/2022]
Abstract
In the last decade organ preservation protocols based on chemoradiotherapy (CRT) has been showing the possibility of preserving function without jeopardizing survival for locally advanced head and neck squamous cell carcinoma (HNSCC). Still, only a percentage of the patients will benefit from this approach and, to date, no biomarkers are known to correctly predict these patients. More recently, modern mass spectrometry method has been used to determine metabolic profiles, and lipidomics, in particular, emerged as a new field of study in oncology and other diseases. This study aimed to analyze the lipid profile on saliva from patients undergoing to a prospective, single center, open-label, non-randomized phase II trial for organ preservation on HNSCC. The lipid analysis was performed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS). Multivariate statistical analyses based on principal component analysis and orthogonal partial least square-discriminant analysis were applied to MALDI-TOF-MS data to visualize differences between the lipid profiles and identify potential biomarkers. The results assisted on distinguishing complete responders from non-responders to the treatment protocol. In conclusion, we demonstrated that a group of lipids is differentially abundant in saliva from HNSCC patients submitted to an organ preservation protocol, being able to differentiate responders from non-responders. These results suggest the potential use of lipid biomarkers to identify patients who may benefit from this treatment. Also, we showed that saliva testing might be routinely used in clinical practice, for being a non-invasive alternative to blood testing, besides inexpensive and easy to obtain.
Collapse
|
4
|
Guenne C, Fayette J, Cosmidis A, Fuchsmann C, Tartas S, Favrel V, Céruse P. Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck. DRUG DESIGN DEVELOPMENT AND THERAPY 2014; 8:2549-53. [PMID: 25548517 PMCID: PMC4271786 DOI: 10.2147/dddt.s70451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Background No specific study has focused on patients with metastatic squamous cell carcinoma of the head and neck (SCCHN) at diagnosis. Due to high response rates of induction chemotherapy in chemo-naïve patients with localized disease, their prognosis should be better than patients with recurrent disease. Methods From January 1, 2008 to July 1, 2012, we retrospectively collected all patients’ records with SCCHN diagnosed as metastatic. Patients, disease, treatment and its results were analyzed. Survival was calculated using the Kaplan–Meier method. Results Of the 749 new patients treated for SCCHN in our institution, 16 (2.1%) were metastatic at diagnosis, of whom five had cytological results to prove it. Six patients died before treatment or had palliative care and ten received initial chemotherapy and then surgery and/or radiotherapy according to the primary response. Four patients treated with first-line chemotherapy with docetaxel-5FU-cisplatin (TPF) showed a complete response of metastatic lesions allowing locoregional treatment. The overall survival at 1 year and 3 years was 50% and 24%, respectively. The median survival was 7 months (1–72 months). Seven patients (43.7%) had a higher survival at 12 months, including five (31.5%) who are still alive without recurrence with a mean follow-up of 30 months. There was a significant difference in overall survival (P<0.01) between patients who had chemotherapy with TPF versus other therapeutic protocols. The median survival of patients with lung metastases only was 15 months (1–72 months), significantly higher than that of patients with liver and/or bone localizations, which was 2 months (1–9 months). Conclusion Patients with metastatic SCCHN treated by TPF followed by multimodal treatment could achieve long survival.
Collapse
Affiliation(s)
- Clémence Guenne
- Head and Neck Surgery Department, Lyon-I University, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| | - Jérôme Fayette
- Medicine Department, Lyon-I University, Centre Léon Bérard, Lyon, France
| | - Alain Cosmidis
- Head and Neck Surgery Department, Lyon-I University, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| | - Carine Fuchsmann
- Head and Neck Surgery Department, Lyon-I University, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| | - Sophie Tartas
- Medical Oncology Department, Lyon-I University, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| | - Véronique Favrel
- Radiotherapy Department, Lyon-I University, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| | - Philippe Céruse
- Head and Neck Surgery Department, Lyon-I University, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| |
Collapse
|
5
|
Current treatment of T1N0 squamous cell carcinoma of the glottic larynx. Eur Arch Otorhinolaryngol 2014; 272:1821-4. [PMID: 25381098 DOI: 10.1007/s00405-014-3388-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Accepted: 10/30/2014] [Indexed: 10/24/2022]
|
6
|
Autophagy interplays with apoptosis and cell cycle regulation in the growth inhibiting effect of Trisenox in HEP-2, a laryngeal squamous cancer. Pathol Oncol Res 2014; 21:103-11. [PMID: 24838151 DOI: 10.1007/s12253-014-9794-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Accepted: 05/06/2014] [Indexed: 02/02/2023]
Abstract
Laryngeal squamous cell carcinoma (LSCC) is the most common among several types of head and neck cancers. Current treatments have a poor effect on early and advanced cases, and further investigations for novel agents against LSCCs are desirable. In this study, we elucidate the cytotoxic enhancing effect of arsenic trioxide (As2O3) combined with L-buthionine sulfoximine (BSO) in LSCC. The effect of BSO with As2O3 or Cisplatin (CDDP) on cell viability was examined using 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The reactive oxygen species (ROS) levels, cell cycle, and apoptosis were measured by flow cytometry using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA), propidium iodide (PI) and annexin V/PI. The acidic vacuolar organelles were visualized by fluorescence microscope and quantified using flow cytometry. Neither CDDP nor As2O3 when used alone reduced the cell viability. BSO was found to enhance only As2O3 sensitivity, leading to G2/M arrest and autophagy with no correlation of ROS induction. This result suggests that modulation of glutathione enhances autophagy, which interplays with apoptosis. In this study, we obtained initial preclinical evidence for the potential efficacy of these drugs in a combined therapy protocol.
Collapse
|
7
|
When is chemotherapy in head and neck squamous cell carcinoma not indicated? Eur Arch Otorhinolaryngol 2014; 272:781-787. [PMID: 24525999 DOI: 10.1007/s00405-014-2894-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Accepted: 01/16/2014] [Indexed: 01/30/2023]
|
8
|
Strojan P, Haigentz M, Bradford CR, Wolf GT, Hartl DM, Langendijk JA, Rinaldo A, Eisbruch A, Mendenhall WM, Forastiere AA, Takes RP, Ferlito A. Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. Oral Oncol 2012; 49:283-6. [PMID: 23219843 DOI: 10.1016/j.oraloncology.2012.11.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2012] [Revised: 11/08/2012] [Accepted: 11/11/2012] [Indexed: 10/27/2022]
|
9
|
Haigentz M, Hartl DM, Silver CE, Langendijk JA, Strojan P, Paleri V, de Bree R, Machiels JP, Hamoir M, Rinaldo A, Paccagnella D, Shaha AR, Takes RP, Ferlito A. Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. Oral Oncol 2012; 48:787-93. [PMID: 22516376 DOI: 10.1016/j.oraloncology.2012.03.019] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Accepted: 03/08/2012] [Indexed: 12/14/2022]
Abstract
Distant metastases from head and neck squamous cell carcinoma (HNSCC), though rare at initial presentation, remain an important manifestation of cancer recurrence and mortality. Although generally considered incurable with a dismal prognosis despite palliative therapy, highly selected patients with distant metastases may have a long term survival benefit from aggressive surgery or radiotherapy. Advances in systemic treatments also may improve patient survival. This article reviews the current state of management of HNSCC patients with distant metastases.
Collapse
Affiliation(s)
- Missak Haigentz
- Department of Medicine (Oncology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Yu Q, Zhang X, Ji C, Yang H, Gao M, Hong S, Hu G. Survival analysis of laryngeal carcinoma without laryngectomy, radiotherapy, or chemotherapy. Eur Arch Otorhinolaryngol 2011; 269:2103-9. [DOI: 10.1007/s00405-011-1873-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2011] [Accepted: 11/29/2011] [Indexed: 10/14/2022]
|
11
|
Schultz P. Vocal fold cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128:301-8. [PMID: 21959270 DOI: 10.1016/j.anorl.2011.04.004] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2010] [Revised: 04/03/2011] [Accepted: 04/16/2011] [Indexed: 11/17/2022]
Abstract
Ninety percent of vocal fold cancers take the form of squamous cell carcinoma. Since the 1980s, incidence in France has been constantly falling in males while increasing in females. The main risk factor is smoking, alcohol being less implicated than in other laryngeal or extralaryngeal locations. Vocal fold squamous cell carcinoma generally develops on healthy mucosa, although primary precancerous lesions such as leukoplakia or papillomatous keratosis are also frequent. The tumor usually originates in the non-lymphophilic mucosal free edge of the vocal fold then invades the various anatomic subunits of the larynx, acquiring lymph-node metastatic potential. Dysphonia is the first presenting symptom, initially caused by defective mucosal vibration and then by impaired mobility and finally fixation of the vocal fold. Extension, risk factor and pretreatment assessments are as in other upper-aerodigestive-tract cancer locations. The possibilities of laryngoscopic exposure and the tumor limits, however, need to be precisely determined if transoral resection is to be considered. For small tumors, surgery or exclusive radiation therapy can be suggested to the patient as part of an individual treatment plan, each having its advantages and drawbacks. Cutting-edge teams report 5-year local control rates of 85-95% in T1-class tumor and 60-90% in T2. Whatever the treatment option, smoking cessation, close surveillance and cardiovascular prevention enable screening of other oncologic locations and limit onset of the other pathologies implicated in most deaths.
Collapse
Affiliation(s)
- P Schultz
- Service d'ORL et de chirurgie cervicofaciale, hôpital de Hautepierre, hôpitaux universitaires de Strasbourg, avenue Molière, 67098 Strasbourg cedex, France.
| |
Collapse
|
12
|
Torrente MC, Rodrigo JP, Haigentz M, Dikkers FG, Rinaldo A, Takes RP, Olofsson J, Ferlito A. Human papillomavirus infections in laryngeal cancer. Head Neck 2011; 33:581-6. [PMID: 20848441 DOI: 10.1002/hed.21421] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Although the association and clinical significance of human papillomavirus (HPV) infections with a subset of head and neck cancers, particularly for oropharyngeal carcinoma, has recently been well documented, the involvement of HPV in laryngeal cancer has been inadequately evaluated. Herein we review the currently known associations of HPV infections in diseases of the larynx and their potential for oncogenicity. Using several methods of detection, HPV DNA has been detected in benign (papillomatosis), indolent (verrucous carcinoma), and malignant (squamous cell carcinoma) lesions of the larynx. Consistent with the known oncogenic risk of HPV infections, common HPV types associated with laryngeal papillomatosis include low-risk HPV types 6 and 11, with high-risk HPV types 16 and 18 more commonly present in neoplastic lesions (verrucous carcinoma and squamous cell carcinoma). Although a broad range of prevalence has been noted in individual studies, approximately 25% of laryngeal squamous cell carcinomas harbor HPV infections on meta-analysis, with common involvement of high-risk HPV types 16 (highest frequency) and 18. Preliminary results suggest that these high-risk HPV infections seem to be biologically relevant in laryngeal carcinogenesis, manifested as having viral DNA integration in the cancer cell genome and increased expression of the p16 protein. Despite this knowledge, the clinical significance of these infections and the implications on disease prevention and treatment are unclear and require further investigation.
Collapse
Affiliation(s)
- Mariela C Torrente
- Departamento de Otorrinolaringologia, Universidad de Chile, Santiago de Chile, Chile
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Haigentz Jr M, Silver CE, Hartl DM, Takes RP, Rodrigo JP, Robbins KT, Rinaldo A, Ferlito A. Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin Pharmacother 2010; 11:1305-16. [DOI: 10.1517/14656561003749256] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Missak Haigentz Jr
- Montefiore Medical Center, Albert Einstein College of Medicine, Division of Oncology, Department of Medicine, Bronx, NY, USA
| | - Carl E Silver
- Montefiore Medical Center, Albert Einstein College of Medicine, Departments of Surgery and Otolaryngology-Head and Neck Surgery, Bronx, NY, USA
| | - Dana M Hartl
- Institut Gustave Roussy, Department of Otolaryngology-Head and Neck Surgery, Villejuif Cedex, France
- Laboratoire de Phonétique et de Phonologie, Sorbonne Nouvelle, Paris, France
| | - Robert P Takes
- Radboud University Nijmegen Medical Center, Department of Otolaryngology-Head and Neck Surgery, Nijmegen, The Netherlands
| | - Juan P Rodrigo
- Department of Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain
- Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - K Thomas Robbins
- Southern Illinois University School of Medicine, Division of Otolaryngology-Head and Neck Surgery, Springfield, IL, USA
| | - Alessandra Rinaldo
- Department of Surgical Sciences, Professor and Chairman of the ENT Clinic, University of Udine, Azienda Ospedaliero-Universitaria, Piazzale S. Maria della Misericordia, I-33100 Udine, Italy ;
| | - Alfio Ferlito
- Department of Surgical Sciences, Professor and Chairman of the ENT Clinic, University of Udine, Azienda Ospedaliero-Universitaria, Piazzale S. Maria della Misericordia, I-33100 Udine, Italy ;
| |
Collapse
|
14
|
Haigentz M, Silver CE, Corry J, Genden EM, Takes RP, Rinaldo A, Ferlito A. Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009; 266:1845-55. [DOI: 10.1007/s00405-009-1109-2] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Haigentz M, Silver CE, Rinaldo A, Ferlito A. Definitive chemotherapy: a new frontier in the fight against laryngeal cancer. Eur Arch Otorhinolaryngol 2009; 267:1-4. [DOI: 10.1007/s00405-009-1105-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Accepted: 08/31/2009] [Indexed: 11/28/2022]
|
16
|
Silver CE, Beitler JJ, Shaha AR, Rinaldo A, Ferlito A. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009; 266:1333-52. [PMID: 19597837 DOI: 10.1007/s00405-009-1028-2] [Citation(s) in RCA: 176] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2009] [Accepted: 06/18/2009] [Indexed: 11/24/2022]
Affiliation(s)
- Carl E Silver
- Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
| | | | | | | | | |
Collapse
|